#United States #New York #Viking Therapeutics #GLP-1 #NASH

Viking Therapeutics at the Piper Sandler Healthcare Conference

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company devoted to the creation of innovative therapies for metabolic and endocrine disorders, will take part in the Piper Sandler 37th Annual Healthcare Conference. This significant event is scheduled to occur from December 2 to December 4, 2025, in the bustling city of New York, New York.

Conference Details

During the conference, Viking’s management will engage in a fireside chat and various investor meetings. The fireside chat is set to take place on December 2, 2025, from 12:30 to 12:55 PM Eastern Time.

Overview of Viking Therapeutics

Viking Therapeutics is committed to advancing first-in-class or best-in-class therapies targeting various metabolic and endocrine disorders. With two programs currently progressing through clinical trials, the firm utilizes its proficiency in metabolism research to develop groundbreaking therapeutics aimed at enhancing patient outcomes.

Clinical Focus and Innovative Therapies

Viking's clinical pipeline includes several noteworthy programs:

• - VK2735: This novel dual agonist targets GLP-1 and GIP receptors, showing promise for treating diverse metabolic disorders. Preliminary data from a Phase 1 and a Phase 2 trial indicates that VK2735 has a commendable safety and tolerability profile alongside encouraging clinical benefits. An oral formulation is also under evaluation in a Phase 2 trial.
• - VK2809: Another pivotal component of Viking's portfolio, this orally available small molecule selectively targets thyroid hormone receptor beta to treat lipid and metabolic disorders. In a recent Phase 2b study targeting biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosis, VK2809 met both its primary and secondary endpoints. Phase 2a results for non-alcoholic fatty liver disease (NAFLD) also displayed statistically significant reductions in LDL cholesterol and liver fat in patients receiving VK2809 versus those on placebo.
• - VK0214: Focused on the rare disorder X-linked adrenoleukodystrophy (X-ALD), VK0214 is an orally available small molecule that has shown safe tolerability and significant reductions in plasma levels of very long-chain fatty acids in a Phase 1b clinical trial.

Conclusion

Viking Therapeutics is at the forefront of developing novel treatments that aim to address challenging metabolic and endocrine disorders. The upcoming Piper Sandler Healthcare Conference serves as an excellent platform for Viking to showcase its innovative programs and engage with potential investors to further its mission of improving patient health outcomes. For additional information about Viking Therapeutics, please explore their website at www.vikingtherapeutics.com.